Abbott's decision to commercialize Freenome's SimpleScreen colorectal cancer test alongside its existing Cologuard Plus offering represents a significant strategic pivot in how the diagnostics giant intends to dominate early cancer detection. Rather than consolidating screening methodologies, Abbott is effectively doubling down on choice—a move that reveals both the complexity of the CRC screening market and the company's confidence in capturing market share across different patient populations and physician preferences.
The timing and structure of this announcement deserve closer scrutiny. Abbott acquired Exact Sciences for $21 billion, primarily to secure Cologuard Plus, a non-invasive stool-based DNA test that disrupted the colorectal cancer screening landscape over the past decade. Cologuard established itself by offering an alternative to colonoscopy for average-risk patients, capturing meaningful market penetration among those who delayed or avoided traditional screening. Now, by adding SimpleScreen—a blood-based biomarker test that analyzes circulating tumor DNA—Abbott is acknowledging that no single screening modality will monopolize the market.
Why Two Tests Matter More Than One
This dual-track approach matters significantly for health system leaders evaluating screening programs. Blood tests and stool tests appeal to different patient segments and clinical workflows. Blood-based screening may attract higher patient compliance in certain demographics, particularly those uncomfortable with stool collection. For health systems managing population health initiatives, blood tests conducted during routine office visits create natural touchpoints. Meanwhile, stool-based tests remain valuable for patients preferring home collection or those with certain contraindications to blood draws.
From a reimbursement perspective, having competing modalities under one corporate umbrella could streamline contracting negotiations. Payers currently face fragmentation across multiple vendors, each claiming superior performance metrics. Abbott can now position itself as offering validated choices rather than forcing either-or decisions, potentially simplifying coverage discussions and reducing administrative friction for health systems managing multiple screening contracts.
However, this strategy also reveals underlying market uncertainty. If either test were definitively superior, Abbott would likely phase out the weaker performer. The simultaneous launch suggests SimpleScreen and Cologuard Plus each address genuine clinical needs that the other doesn't fully satisfy. This creates opportunities but also complexity—health system labs must now manage dual validation, training, and quality assurance protocols, and clinicians need clearer decision trees for which test to recommend to which patients.
For competing vendors, Abbott's maneuver raises the competitive stakes substantially. Exact Sciences' original Cologuard faced competition from other stool-based tests and emerging blood-based alternatives. Now Abbott controls both categories, creating a formidable portfolio that can address nearly every screening preference. Smaller players focusing exclusively on blood-based or stool-based screening may face margin pressure as Abbott leverages integrated sales force relationships to bundle or cross-sell offerings.
The broader implication concerns market consolidation in cancer diagnostics. Abbott's $21 billion Exact Sciences acquisition, combined with this expanded portfolio strategy, demonstrates how major diagnostics players are building end-to-end screening ecosystems rather than betting on single technologies. This trend favors large vendors with distribution scale while potentially marginalizing niche players unable to offer comparable breadth.
For health system leaders, the practical challenge involves optimizing screening programs amid expanding vendor portfolios. Rather than viewing Abbott's dual offering as customer-friendly optionality, procurement teams should demand clear health economic data justifying multiple tests, ensuring purchasing decisions reflect genuine clinical differentiation rather than vendor portfolio ambitions.
Reporting basis: medtechdive.com. Analysis by the HTC editorial desk.